Press ReleasesMateria Malta Completes First Commercial Export Of Medical Cannabis...

Materia Malta Completes First Commercial Export Of Medical Cannabis To Germany

-

Materia (the “Company”), a leading producer and distributor of medical cannabis in Europe, announces that its wholly-owned subsidiary Materia Malta Operating Ltd. (“Materia Malta“) has completed its first export of commercial medical cannabis from its EU GMP manufacturing site.

This represents the launch of Materia’s own brand and manufactured products into Germany, Europe’s largest medical cannabis market. The Company’s German distribution subsidiary, Materia Deutschland GmbH, which took delivery of the shipment, has commenced sales to pharmacies, with a number of pre-orders already received.

Materia becomes the first Malta-based manufacturer of medical cannabis to export product for commercial sale in another country. Previous exports have only been approved for R&D or lab testing purposes.

“Our products are already helping patients in Malta improve their quality of life, and now we can support the needs of patients in Germany too,” said Nick Pateras, Managing Director, Europe of Materia.

“We believe Malta will play an important role in the global cannabis supply chain, as it has done within the broader pharmaceuticals sector for decades. We are proud to be the company establishing new frontiers for Malta’s and Europe’s cannabis industry.”

Update on Kanabo Transaction

The Company also informs that further to the announcements made on 26 July, 2021 and 4 November, 2021 regarding its proposed transaction with Kanabo Group Plc (“Kanabo”), discussions have developed such that both parties believe the relationship is best consummated through a contract manufacturing agreement, as opposed to the previously proposed transaction.  

The Company is seeking new strategic partners while it continues its organic growth and execution of its business plan. Discussions with potential partners are oriented around accelerating the Company’s penetration of key end markets and further bolstering its supply chain.

Latest news

MGC Pharmaceuticals Releases Update On CimetrA Clinical Trial Progress In USA

MGC Pharmaceuticals Ltd (ASX, LSE: MXC, ‘MGC Pharma’ or ‘the Company’), a European based bio-pharma company specialising in the production and development...

European Cannabis Stocks Review: Akanda’s ‘Concerned Shareholders’ Oust All Directors Except CEO To Prevent ‘Potentially Irreparable Harm’ – More From Goodbody Health & Chill...

It has been another week of positive developments for the cannabis industry across Europe, with yet more markets making...

Analysis Shows UK Market Could Grow To Over £1bn By 2026 As London Prepares To Host Europe’s Leading Cannabis Conference

ANALYSIS shows UK market could grow to over £1bn by 2026 as London prepares to host Europe’s leading cannabis...

Medical Cannabis Could Be Available In Spain By The End Of The Year

SPAIN could now see the regulation and distribution of medical cannabis rolled out before the end of the year...

New UK Company Heralds Its ‘Unique’ Medical Cannabis Delivery Mechanism

CANNABIS extraction and formulations specialist 113 Botanicals is in the process of securing Good manufacturing Practice (GMP) compliance for...

German Cannabis Bill By Year End With Adult-Use Launch Likely In Early 2024

GERMANY’s draft cannabis law should be ready by the end of the year with the launch of its adult-use...

Must read

You might also likeRELATED
Recommended to you